- Home
- INDV
INDV
Indivior PLC
as of 03-19-2026 12:41pm EST
$30.47
+$0.02
+0.07%
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NORTH CHESTERFIELD |
| Market Cap: | 4.0B | IPO Year: | 2014 |
| Target Price: | N/A | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.64 | EPS Growth: | 8100.00 |
| 52 Week Low/High: | $8.64 - $38.00 | Next Earning Date: | 06-08-2026 |
| Revenue: | $1,239,000,000 | Revenue Growth: | 4.29% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | 18.62 | Index: | N/A |
| Free Cash Flow: | -93000000.0 | FCF Growth: | N/A |
AI-Powered INDV Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 17 hours ago
AI Recommendation
hold
Model Accuracy: 76.92%
76.92%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Indivior PLC (INDV)
Ryan Barbara
Buy
Director
INDV Mar 13, 2026
Avg Cost/Share
$31.09
Shares
8
Total Value
$248.68
Owned After
5,724
SEC Form 4
Ryan Barbara
Buy
Director
INDV Mar 9, 2026
Avg Cost/Share
$32.56
Shares
31
Total Value
$1,009.36
Owned After
5,724
SEC Form 4
Kingsley Stuart A
Buy
Director
INDV Mar 6, 2026
Avg Cost/Share
$31.87
Shares
940
Total Value
$29,953.10
Owned After
5,582
SEC Form 4
Ryan Barbara
Buy
Director
INDV Jan 5, 2026
Avg Cost/Share
$35.39
Shares
775
Total Value
$27,429.27
Owned After
5,724
SEC Form 4
NINIVAGGI DANIEL A
Buy
Director
INDV Jan 5, 2026
Avg Cost/Share
$35.39
Shares
775
Total Value
$27,429.27
Owned After
16,923
SEC Form 4
Wheadon David E.
Buy
Director
INDV Jan 5, 2026
Avg Cost/Share
$35.39
Shares
1,771
Total Value
$62,680.29
Owned After
14,395
SEC Form 4
Humphreys Keith
Buy
Director
INDV Jan 5, 2026
Avg Cost/Share
$35.39
Shares
775
Total Value
$27,429.27
Owned After
5,802
SEC Form 4
Stejbach Mark
Buy
Director
INDV Jan 5, 2026
Avg Cost/Share
$35.39
Shares
775
Total Value
$27,429.27
Owned After
16,847
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Ryan Barbara | INDV | Director | Mar 13, 2026 | Buy | $31.09 | 8 | $248.68 | 5,724 | |
| Ryan Barbara | INDV | Director | Mar 9, 2026 | Buy | $32.56 | 31 | $1,009.36 | 5,724 | |
| Kingsley Stuart A | INDV | Director | Mar 6, 2026 | Buy | $31.87 | 940 | $29,953.10 | 5,582 | |
| Ryan Barbara | INDV | Director | Jan 5, 2026 | Buy | $35.39 | 775 | $27,429.27 | 5,724 | |
| NINIVAGGI DANIEL A | INDV | Director | Jan 5, 2026 | Buy | $35.39 | 775 | $27,429.27 | 16,923 | |
| Wheadon David E. | INDV | Director | Jan 5, 2026 | Buy | $35.39 | 1,771 | $62,680.29 | 14,395 | |
| Humphreys Keith | INDV | Director | Jan 5, 2026 | Buy | $35.39 | 775 | $27,429.27 | 5,802 | |
| Stejbach Mark | INDV | Director | Jan 5, 2026 | Buy | $35.39 | 775 | $27,429.27 | 16,847 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K Feb 26, 2026
2025
Q4
Q4 2025 Earnings
8-KFeb 26, 2026
0001193125-26-073363
8-K
false 0001625297 0001625297 2026-02-26 2026-02-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026
INDIVIOR PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-37835
41-2520873
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
10710 Midlothian Turnpike, Suite 125 North Chesterfield, VA
23235
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: 804-379-1040 n/a (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
common stock, $0.001 par value per share
INDV
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On February 26, 2026, Indivior Pharmaceuticals, Inc. (“Indivior” or the “Company”) issued a press release reporting its financial results for the period ended December 31, 2025. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 7.01 Regulation FD Disclosure.
On February 26, 2026, the Company posted presentation materials on its website. The presentation materials are furnished as 99.2 to this Current Report on Form 8-K. Also on February 26, 2026, the Company updated its corporate presentation which is posted on its website. The corporate presentation is furnished as Exhibit 99.3 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press Release dated February 26, 2026.
99.2
Presentation materials dated February 26, 2026.
99.3
Corporate presentation dated February 26, 2026.
104
Cover page interactive data file (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Indivior Pharmaceuticals, Inc.
Date: February 26, 2026
By:
/s/ Ryan Preblick
Name:
Ryan Preblick
Title:
Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Oct 30, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 30, 2025
0001193125-25-257381
8-K
false 0001625297 0001625297 2025-10-30 2025-10-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025
INDIVIOR PLC
(Exact name of registrant as specified in its charter)
England and Wales
001-37835
98-1204773
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
10710 Midlothian Turnpike, Suite 125
North Chesterfield, VA
23235
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: 804-379-1040
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Ordinary shares, $0.50 nominal value per share
INDV
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On October 30, 2025, Indivior PLC (“Indivior” or the “Company”) issued a press release reporting its financial results for the period ended September 30, 2025. The press release is furnished as Exhibits 99.1 to this Current Report on Form 8-K.
Item 7.01 Regulation FD Disclosure.
On October 30, 2025, the Company posted presentation materials on its website. The presentation materials are furnished as 99.2 to this Current Report on Form 8-K. Also on October 30, 2025, the Company updated its corporate presentation materials which are posted on its website. The corporate presentation is furnished as Exhibit 99.3 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
Exhibit No.
Description
99.1
Press release issued by Indivior PLC dated October 30, 2025.
99.2
Presentation materials dated October 30, 2025.
99.3
Corporate Presentation updated October 30, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Indivior PLC
Date: October 30, 2025
By:
/s/ Ryan Preblick
Name: Ryan Preblick
Title: Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Jul 31, 2025
2025
Q2
Q2 2025 Earnings
8-KJul 31, 2025
0001193125-25-169947
8-K
false 0001625297 0001625297 2025-07-31 2025-07-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025
INDIVIOR PLC
(Exact name of registrant as specified in its charter)
England and Wales
001-37835
98-1204773
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
10710 Midlothian Turnpike Suite 125 North Chesterfield, VA
23235
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: 804-379-1040
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Ordinary shares, $0.50 nominal value per share
INDV
The Nasdaq Stock Market LLC
Indicate by check mark
INDV
London Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On July 31, 2025, Indivior PLC (“Indivior” or the Company) issued a press release reporting its financial results for the period ended June 30, 2025 and posted on its website the press release and related presentation materials. The press release and related presentation materials are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.
Item 7.01 Regulation FD Disclosure.
On July 31, 2025, the Company updated its corporate presentation materials. The corporate presentation is furnished as Exhibit 99.3 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
Exhibit No.
Description
99.1
Press release issued by Indivior PLC dated July 31, 2025.
99.2
Presentation materials dated July 31, 2025.
99.3
Corporate Presentation updated July 31, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Indivior PLC
Date: July 31, 2025
By:
/s/ Ryan Preblick
Name:
Ryan Preblick
Title:
Chief Financial Officer
Latest Indivior PLC News
INDV Breaking Stock News: Dive into INDV Ticker-Specific Updates for Smart Investing
Compare INDV vs Leading Stocks
See how INDV stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "INDV Indivior PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.